© 2016 Market data provided and hosted by Barchart Market Data Solutions. Fundamental company data provided by Morningstar and Zacks Investment Research. Information ...
Acceptance based on objective response rate data from the Phase 2 LITESPARK-015 trial evaluating WELIREG in certain patients with advanced PPGL If approved, WELIREG would be the only available therapy ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
At close: January 17 at 4:12:21 PM GMT+7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback